Inactive Instrument

Zosano Pharma Corporation

ZSAN

US98979H3012

Biotechnology & Medical Research

Zosano Pharma Corporation Appoints Kenneth Greathouse as Member of the Audit Committee

October 10, 2019 at 04:55 pm EDT

On October 10, 2019, the Board of Zosano Pharma Corporation appointed Kenneth Greathouse, a current member of the Board, effective immediately, to serve as a member of the Audit Committee.

Latest news about Zosano Pharma Corporation

Zosano Pharma Corporation Went Out of Business	22-12-06	CI
Second Amended Liquidation Plan Approved for Zosano Pharma Corporation	22-11-22	CI
Second Amended Liquidation Plan Filed by Zosano Pharma Corporation	22-11-21	CI
First Amended Liquidation Plan Filed by Zosano Pharma Corporation	22-11-17	CI
First Amended Disclosure Statement Filed by Zosano Pharma Corporation	22-10-10	CI
Disclosure Statement Approved for Zosano Pharma Corporation	22-10-07	CI
First Motion for Exclusivity Period Extension Filed by Zosano Pharma Corporation	22-09-21	CI
Liquidation Plan and Disclosure Statement Filed by Zosano Pharma Corporation	22-08-25	CI
Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.	22-08-24	CI
Motion for Asset Sale Approved for Zosano Pharma Corporation	22-08-08	CI
Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.	22-07-25	CI
Bidding Procedure Approved for Zosano Pharma Corporation	22-07-01	CI
Motion for Case Conversion Filed for Zosano Pharma Corporation	22-06-22	CI
Zosano Pharma Corporation(OTCPK:ZSAN.Q) dropped from NASDAQ Composite Index	22-06-10	CI
Motion for Asset Sale Filed by Zosano Pharma Corporation	22-06-09	CI
Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from S&P TMI Index	22-06-07	CI
Zosano Pharma Files for Chapter 11 Bankruptcy	22-06-02	MT
Zosano Pharma Plans to Sell Assets	22-06-01	CI
Zosano Pharma Corporation Filed for Bankruptcy	22-06-01	CI
Zosano Pharma Tumbles After-Hours on Going Concern Warning, Higher Q1 Loss	22-05-13	MT
Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation	22-05-13	CI
Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022	22-05-13	CI
Zosano Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Certain Common Stock of Zosano Pharma Corporation are subject to a Lock-Up Agreement Ending on 10-MAY-2022.	22-05-09	CI
Certain Warrants of Zosano Pharma Corporation are subject to a Lock-Up Agreement Ending on 10-MAY-2022.	22-05-09	CI

Chart Zosano Pharma Corporation

Duration

Period

More charts

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. It is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.41%	22.28B
GENMAB A/S	-5.48%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs